What one share of Apollomics holds
We are a clinical-stage biotechnology company focused on discovering and developing oncology therapies to address unmet medical needs, especially for difficult-to-treat and treatment-resistant cancers. Since our founding in 2015, we have built a pipeline focused on oncology, of which three product candidates remain in active clinical stage development.
Apollomics’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Sales | $5.88 |
|---|---|
| Profit | −$7.57 |
| Dividends | $0.00 |
| Cash and investments | $2.27 |
| Debt | $0.00 |
| Book value | −$2.20 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | $0.00 | −$337.27 | $0.18 | −$154.27 | — | −$757.32 |
| 2022 | — | −$844.95 | $1.29 | −$151.55 | — | −$1,572 |
| 2023 | $0.00 | −$231.99 | $0.01 | −$58.08 | — | $46.07 |
| 2024 | $0.00 | −$52.80 | $0.02 | −$28.20 | — | $4.41 |
| 2025 | $5.88 | −$7.57 | — | — | — | −$2.20 |
Common questions about Apollomics
How much does one share of Apollomics earn?
Over its latest fiscal year, Apollomics lost $7.57 for each share on $5.88 of sales.
Does Apollomics pay a dividend?
Apollomics didn’t pay a dividend over its latest fiscal year, according to its SEC filings.
What is Apollomics’s book value per share?
Apollomics’s book value is negative (−$2.20 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of December 31, 2025.
How much cash and debt does each share of Apollomics have?
Each share of Apollomics has $2.27 of cash and investments and $0.00 of debt, as of December 31, 2025.
Has Apollomics bought back shares?
Apollomics’s share count rose about 414% from 2021 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.